- Anaphylaxis has occurred with MEPSEVII administration, as early as the first dose, therefore appropriate medical support shouldbe readilyavailable when MEPSEVII is administered.
- Closely observe patients during and for 60 minutes after MEPSEVII infusion.
- Immediately discontinue the MEPSEVII infusion if the patient experiences anaphylaxis
Patient Counseling Information
Updated April 2018